<SEC-DOCUMENT>0001628280-24-045998.txt : 20241107
<SEC-HEADER>0001628280-24-045998.hdr.sgml : 20241107
<ACCEPTANCE-DATETIME>20241107080313
ACCESSION NUMBER:		0001628280-24-045998
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241107
DATE AS OF CHANGE:		20241107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VYNE Therapeutics Inc.
		CENTRAL INDEX KEY:			0001566044
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				453757789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38356
		FILM NUMBER:		241433287

	BUSINESS ADDRESS:	
		STREET 1:		685 ROUTE 202/206 N., SUITE 301
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		800-775-7936

	MAIL ADDRESS:	
		STREET 1:		685 ROUTE 202/206 N., SUITE 301
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics Inc.
		DATE OF NAME CHANGE:	20180201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170728

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tigercat Pharma, Inc.
		DATE OF NAME CHANGE:	20130104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mnlo-20241107.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:270d7956-ecb1-48bb-86fa-16d990fd5f4d,g:a2282323-2933-43c6-b0b1-5f97d8ad491e,d:3dec01e9274d4ed58cf162c2212afb34-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mnlo-20241107</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-21">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001566044</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mnlo-20241107.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-07</xbrli:startDate><xbrli:endDate>2024-11-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3dec01e9274d4ed58cf162c2212afb34_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported) <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 7, 2024</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">VYNE Therapeutics Inc</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38356</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">45-3757789</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IRS Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">685 Route 202/206 N., Suite 301</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Bridgewater</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">08807</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices, including Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">800</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">775-7936</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K&#160;filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12&#160;under the Exchange Act (17 CFR&#160;240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement&#160;communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR&#160;240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement&#160;communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR&#160;240.13e-4(c))</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.066%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">VYNE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934&#160;(&#167;240.12b-2&#160;of this chapter). Emerging growth company&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3dec01e9274d4ed58cf162c2212afb34_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;7, 2024, VYNE Therapeutics Inc. issued a press release announcing its financial results for the quarter ended September&#160;30, 2024. The press release is being furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="i3dec01e9274d4ed58cf162c2212afb34_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Exhibits</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-20241107q32024exx991.htm">Press release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-20241107q32024exx991.htm">November</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-20241107q32024exx991.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-20241107q32024exx991.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-20241107q32024exx991.htm">, 2024</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i3dec01e9274d4ed58cf162c2212afb34_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.076%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;7, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Mutya Harsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutya Harsch<br/>Chief Legal Officer and General Counsel</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vyne-20241107q32024exx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i877adb53779c4fc19dcfee7734bb0d38_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font><br></font></div><div><img alt="image.jpg" src="image.jpg" style="height:69px;margin-bottom:5pt;vertical-align:text-bottom;width:274px"></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">VYN201 Phase 2b vitiligo trial exceeds enrollment target&#59; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Reported positive first-in-human Phase 1a SAD data for VYN202, with MAD data expected in Q4 2024 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BRIDGEWATER, N.J., November&#160;7, 2024 -- VYNE Therapeutics Inc. (Nasdaq&#58; VYNE) (&#8220;VYNE&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the three and nine months ended September&#160;30, 2024 and provided a business update. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8220;We continue to make excellent progress in advancing our two InhiBET&#8482; clinical programs VYN201 and VYN202, and believe each product candidate has the potential to be a differentiated, class-leading therapy for immune-mediated diseases,&#8221; said David Domzalski, President and Chief Executive Officer of VYNE. &#8220;We recently reported positive SAD data from our Phase 1a SAD&#47;MAD trial of oral, BD2-selective BET inhibitor, VYN202, and we anticipate reporting data from the MAD portion of the trial later this quarter. We are encouraged by the strong enrollment in our ongoing Phase 2b trial for VYN201 which we believe underscores the significant unmet need in the treatment of vitiligo. We expect to complete enrollment next month and report topline data mid- next year.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recent Pipeline Updates </font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">VYN201, a locally-administered small molecule pan-BD BET inhibitor&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Phase 2b trial of VYN201 in nonsegmental vitiligo exceeds initial enrollment target and expected to complete enrollment next month.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Phase 2b trial is expected to be fully enrolled in December 2024, with approximately 40 to 50 subjects per arm. The trial was initiated in June 2024 and VYNE expects to report top-line results from the 24-week double-blind portion of the trial in mid-2025.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The Phase 2b trial (NCT06493578) is a randomized, double-blind, vehicle-controlled trial evaluating the efficacy, safety and pharmacokinetics of once-daily VYN201 gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. Subjects are being randomized equally (1&#58;1&#58;1&#58;1 ratio) across the active drug cohorts or vehicle. Following the 24-week treatment period, subjects who have been randomized in the three dose cohorts will have the option to continue treatment with their respective dose concentrations for an additional 28-week extension. Subjects who have been randomized in the vehicle group during the initial 24-week treatment period will be equally re-randomized into one of the three active dose cohorts for an additional 28 weeks.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">VYN202, an oral small molecule BD2-selective inhibitor&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">VYNE expects to report top-line results from the multiple ascending dose (&#8220;MAD&#8221;) portion of the Phase 1a trial in the fourth quarter of 2024.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Data from the single ascending dose (&#8220;SAD&#8221;) portion of the trial, announced in September 2024, showed that VYN202 was generally well tolerated with no drug related adverse events. Assessment of key pharmacokinetic and pharmacodynamic parameters demonstrated dose dependent drug concentrations of VYN202 in the blood and showed pharmacodynamic impact of VYN202 on key target-engagement and inflammatory biomarkers in whole blood assays, including an inhibitory effect on select inflammatory biomarkers relevant to psoriasis and rheumatoid arthritis. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Pending successful completion of the Phase 1a trial, VYNE plans to initiate Phase 1b trials in adult subjects with moderate-to-severe plaque psoriasis and moderate-to-severely active rheumatoid arthritis, with top-line results anticipated in the second half of 2025. </font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Financial Results as of and for the Third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Quarter Ended September&#160;30, 2024</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash position. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2024, VYNE had cash, cash equivalents, restricted cash and marketable securities of $70.2 million. VYNE believes its cash, cash equivalents, restricted cash and marketable securities as of September&#160;30, 2024 will be sufficient to fund its operations through the end of 2025. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share count.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> As of September&#160;30, 2024, VYNE had 14,751,433 shares issued and outstanding, and outstanding pre-funded warrants to purchase 27,842,740 shares of common stock at an exercise price of $0.0001 per share. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenues. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenues totaled $0.1 million for both the quarters ended September&#160;30, 2024 and 2023, respectively, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma, to whom VYNE previously licensed the rights to Finacea</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> foam.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. VYNE&#8217;s research and development expenses for the quarter ended September&#160;30, 2024 were $10.2 million, representing an increase of $6.9 million, or 208.9%, compared to $3.3 million for the quarter ended September&#160;30, 2023. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase was primarily driven by increased expenses associated with VYNE's ongoing Phase 2b trial of VYN201 in subjects with nonsegmental vitiligo and its ongoing Phase 1a SAD&#47;MAD trial of VYN202 of $5.0 million and $1.7 million, respectively.  Both trials were initiated in June 2024. In addition, employee-related expenses increased by $0.3 million following the hiring of additional research and development personnel. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">General and administrative expenses. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">VYNE&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">general and administrative expenses for both the quarters ended September&#160;30, 2024 and 2023 were approximately $3.0 million, representing an immaterial change year-over-year.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Net loss. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss and net loss per share for the quarter ended September&#160;30, 2024 were $12.2 million and $0.29, respectively, compared to a net loss and net loss per share of $6.6 million and $2.01, respectively, for the comparable period in 2023.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">About VYNE Therapeutics Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE's unique and proprietary BET inhibitors, which comprise its InhiBET&#8482; platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For more information about VYNE Therapeutics Inc. or its product candidates, visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">www.vynetherapeutics.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE&#8217;s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Investor Relations&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">John Fraunces</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LifeSci Advisors, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">917-355-2395</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">jfraunces&#64;lifesciadvisors.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tyler Zeronda</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VYNE Therapeutics Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">908-458-9106</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tyler.Zeronda&#64;VYNEtx.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Media Relations&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mike Beyer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sam Brown Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">312-961-2502</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">mikebeyer&#64;sambrown.com </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding VYNE's ability to successfully complete its Phase 1a trial of VYN202, future clinical trials of VYN202, the expected enrollment and timing for reporting top-line results from trials of VYN201 and VYN202, VYNE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8217;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">s projected cash runway, and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE&#8217;s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to&#58; VYNE&#8217;s ability to successfully develop its product candidates&#59; the timing of commencement of future preclinical studies and clinical trials&#59; VYNE&#8217;s ability to complete and receive favorable results from clinical trials of its product candidates&#59; VYNE&#8217;s ability to obtain additional funding, either through equity or debt financing transactions or collaboration arrangements&#59; and VYNE&#8217;s ability to comply with various regulations applicable to its business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE&#8217;s actual results to differ from those contained in the forward-looking statements, see the section titled &#8220;Risk Factors&#8221; in VYNE&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, and VYNE&#8217;s other filings from time to time with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Third-party products and company names mentioned herein may be the trademarks of their respective owners.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i877adb53779c4fc19dcfee7734bb0d38_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. dollars in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,272&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,620&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,913&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,633&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Current Assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,535&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,963&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current Assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current prepaid expenses and other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Non-current Assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,198&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,685&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,986&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,168&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Current Liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,661&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,538&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Long-term Liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,661&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,950&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders' Equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock&#58; $0.0001 par value&#59; 20,000,000 shares authorized at September&#160;30, 2024 and December&#160;31, 2023&#59; no shares issued and outstanding at September&#160;30, 2024 and December&#160;31, 2023</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#58; $0.0001 par value&#59; 150,000,000 shares authorized at September&#160;30, 2024 and December&#160;31, 2023&#59; 14,751,433 and 14,098,888 shares issued and outstanding at September&#160;30, 2024 and December&#160;31, 2023, respectively</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,650&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780,044&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(719,148)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(691,336)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders' Equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,537&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,735&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,198&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,685&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i877adb53779c4fc19dcfee7734bb0d38_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. dollars in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,248&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,318&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,284&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,022&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Operating Expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,212&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,348&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,284&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,774&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,091)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,234)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,867)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,426)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,074&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from continuing operations before income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,157)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,071)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,793)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,720)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from continuing operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,157)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,071)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,793)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,720)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(544)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,157)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,584)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,812)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,264)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share from continuing operations, basic and diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.85)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.66)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per share from discontinued operations, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share, basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.01)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.82)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,587&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,592&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mnlo-20241107.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:270d7956-ecb1-48bb-86fa-16d990fd5f4d,g:a2282323-2933-43c6-b0b1-5f97d8ad491e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mnlo="http://www.menlotherapeutics.com/20241107" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.menlotherapeutics.com/20241107">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20241107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20241107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mnlo-20241107_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:270d7956-ecb1-48bb-86fa-16d990fd5f4d,g:a2282323-2933-43c6-b0b1-5f97d8ad491e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_c1c5b813-2b56-42bb-90bf-4004d15524c6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c3f5e4f8-6d3c-4fad-8991-b975979fcb73_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_b96c3015-f6da-457d-9778-6805708a3bba_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c0edfa96-2978-489c-bf9f-79f30469d6c0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d1b1b3d4-fd47-4ad3-8340-9d6ad8228293_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_32ec89f5-8990-44b3-b10e-38f39e789ea6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c26b3484-b04b-42e0-b90a-014c33b83c71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d807299e-7044-4d92-ba8d-1efe5cdc6e2a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d0c7b17e-bb7f-4270-9338-95ef07c0e0e6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0657f28d-98c7-4b29-8411-8db373a8cb85_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f364cf16-9971-4fe6-b565-727e317db37a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ce35a1f1-160d-4077-82e7-d6a8dc7f5068_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_9550e88c-e4f5-49e0-8b76-428dfe8b8930_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3a68f8f4-7953-402f-be99-3fcedd3e3dac_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5fb0f250-8c3e-4585-8b71-4ac9f11e1556_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3fcf3455-bfbd-4093-8318-5ef982694459_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4fc485b3-07b7-4d7b-af8c-efa96c46cb0b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bda15307-7459-444b-a918-dbb7788f5135_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7fc52a8d-292e-4ba2-ab9b-08616b3aecc0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e08d4cad-76c8-47b2-99ca-2fc161bf2fec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_01a5d597-6c5f-42b8-be85-965b90fe4ff7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_60ea45a3-e73f-4c5b-9ffb-262fd4a12084_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0b05cfec-6a96-48d6-a113-6a2db8990883_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mnlo-20241107_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:270d7956-ecb1-48bb-86fa-16d990fd5f4d,g:a2282323-2933-43c6-b0b1-5f97d8ad491e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="mnlo-20241107.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6ff8f55a-b3f7-4998-8ebd-82b3bbfe7f66" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_DocumentType_6ff8f55a-b3f7-4998-8ebd-82b3bbfe7f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ec18c918-2382-4f13-8cc7-d16a4a30905a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_DocumentPeriodEndDate_ec18c918-2382-4f13-8cc7-d16a4a30905a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1bea20c0-24a6-4f99-a493-853fc169af08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_EntityRegistrantName_1bea20c0-24a6-4f99-a493-853fc169af08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dfa4e6fc-eb18-407c-91b2-1825bf7021a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_EntityCentralIndexKey_dfa4e6fc-eb18-407c-91b2-1825bf7021a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b13346fe-a37b-4643-9e02-dcb1054fef0a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_AmendmentFlag_b13346fe-a37b-4643-9e02-dcb1054fef0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_211c671d-e7f5-4526-9a77-3c5ead06e06a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_EntityIncorporationStateCountryCode_211c671d-e7f5-4526-9a77-3c5ead06e06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_91e3bb7f-3803-453b-bd16-b1ced170690b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_EntityFileNumber_91e3bb7f-3803-453b-bd16-b1ced170690b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_880636bf-dafe-4817-b256-e18e90b3cadc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_EntityTaxIdentificationNumber_880636bf-dafe-4817-b256-e18e90b3cadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b5afcd43-2637-4224-8e05-6c6f77414284" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_EntityAddressAddressLine1_b5afcd43-2637-4224-8e05-6c6f77414284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4cb57f5f-1324-447c-ab9e-d5dd7b43235c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_EntityAddressCityOrTown_4cb57f5f-1324-447c-ab9e-d5dd7b43235c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_faa8c81f-7847-4886-9557-1baf3711d02b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_EntityAddressStateOrProvince_faa8c81f-7847-4886-9557-1baf3711d02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_43fcb171-7d43-4abd-ac27-8ec7b7975d2c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_EntityAddressPostalZipCode_43fcb171-7d43-4abd-ac27-8ec7b7975d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_91d48a19-1bcd-4545-afb3-467e2a7f3403" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_CityAreaCode_91d48a19-1bcd-4545-afb3-467e2a7f3403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cef0bd00-b7f7-4197-95ee-657f6da4b0a5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_LocalPhoneNumber_cef0bd00-b7f7-4197-95ee-657f6da4b0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a66bf475-0e7b-4cbe-a3fe-890dc30a28ae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_WrittenCommunications_a66bf475-0e7b-4cbe-a3fe-890dc30a28ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_5d5b91c1-87a9-43f7-8704-fc41c53c52eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_SolicitingMaterial_5d5b91c1-87a9-43f7-8704-fc41c53c52eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_4dcac2c4-0184-4a1c-9b7e-4cb819c2d916" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_PreCommencementTenderOffer_4dcac2c4-0184-4a1c-9b7e-4cb819c2d916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e73be109-3e96-4fc3-8c08-987962e801f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e73be109-3e96-4fc3-8c08-987962e801f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f172654d-8a78-46fc-b373-078bcb93b1ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_Security12bTitle_f172654d-8a78-46fc-b373-078bcb93b1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6385e4e9-de8a-44e2-9e42-dbc8e796b69e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_TradingSymbol_6385e4e9-de8a-44e2-9e42-dbc8e796b69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_68f0c22d-aa56-4deb-85f3-94bd8037b3b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_SecurityExchangeName_68f0c22d-aa56-4deb-85f3-94bd8037b3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_eb21ef71-4cae-4bf4-bc11-7307d7c57eae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d10a64ce-9cdf-450a-b748-565182c09853" xlink:to="loc_dei_EntityEmergingGrowthCompany_eb21ef71-4cae-4bf4-bc11-7307d7c57eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
MB5!.1PT*&@H    -24A$4@   9@   !H" 8   #,WN;X     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  %Q$  !<1 <HF\S\  #Z1241!
M5'A>[7UWF!15^N[]]][[NQM^:P8#9EE77=U=];JKZ]Y=(Z*259(*2 8) H*
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MA_Q+G/KKOWY")'FD5HZEO [:K03#")Q<KWRRI19!O;))C<C:]WE!&DH/.YK
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M+0F&$;A\0$Y9UE/"7T%$P+\16;]Y+CK)X&'P:M*]<:SH _;R;3AGI^\TN,9
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M#?*CY#XLEW[;\JB%?!JE$K' '59OZ75Q#/+$(T648ZL<*_! SCD1[(="4QK
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M\F]$8#^.]0+9_ X%#G5C$]<CMTXT<^YZ^L/]'U(UA3A,I%1[K*&05]_H+K+
M4"13B2STB92ZC/-E*L.Q,B9,F#"13!A#,#Z'M.<%=<44":8:>5<^S^02QW()
M2\8;%#@WF1N^J<7/7\BDYU]I+;+)E(@E4I ,@+C,WU[K2)^WFT@=#"29EAVG
M4,?N,^GRU3RY9R9,F#!A0@F&$$PP[P!YECRBL%L?Y%*=__8P^3:]I<YZP=Z8
MC'<HE'_[WI,6[4;2?U?_D*HKD$I9D4BF/CWS4FMJTG*,O"'3F. _#C&;.FNS
MW"L3)DR8,*$$0P@F<&:R1"X@D]L(!FG)?V-RB9$U%BD9;U+@0$<B[^T;I#9N
M/D3W/=:(I:$BJ2@)2.:)YSZE^B*-V1B2@173OMMT.G<A6^Z9"1,F3)@H"T,(
MQG^@6Y2]+_S_GQ^52K^H(IC:3#!O4_#*$KGE6^%TN:EV@SXB%J-$)M%$I#'7
M;$SOU.TO O]&!/^1MCQM]E8*!LU@C D3)DPHP1""\6UO+-4<NX5<6-AZ\:UY
M28/U\I94@\QKE5N^'3\OWT%W/5A7DQ4#0>"_^N,-Z;4WOQ([\Q.-R^#,_TX]
M9IFQ&!,F3)B(@L0)QN\D[V943(8%$TDNU=EZ>8Q\.-]%#<%@[\N6VA3,VRTW
MK R'PTUU/NI/OZ_V@2*1Q!)LU(0U\\+?VU.S+\:)\C)MOM3O,D/%Y9^6I7^=
M,A,F3)@H#R1,,"%G'GG7_X<\\^^XC6"\:UY4%]C?\C[Y-\F98]AI' =;=QRC
M!Y_\F.YYN+XBD<22<(;9D\]_1O6:#!,[__6ZS'#<\E??S*>B8KO<,Q,F3)@P
M$4;B!&.[1MZUKY%GP9UEK)='R9_!UDN\3940')-\K"];0^I/D>S5=QK]3H<5
M$Y;PSO\W/^A+;;I,$T2C1"*Q!/MLL/ERXY;C<J_2&V<+/33K1 G-.V6)*S..
ME]"VJ['K.)WC]N:>M(@VSQ3<W+-4%NLNV&CZL1):\JN5O('8,2NK)R ^-SM.
M/^?P=1?^8J%\9^S2/:?RW32+[Z7L]^>RX/L;+]GI2HDOX7U-:_D>1^POI*5G
MK+I*N]F]05IYSGK;^T$_%Y^VT'9^%[EV]:5/CN7R?7-;^'YD>V4%[WG'-4?$
MAH#;4>@*T )^5C/YL_LRHY^/=,/A%]><QN_Z0';LN;SEBD-<6ZE/D8+^SSY9
M0A>*8A^9L2_+1>,/%]&/+&>+HH]%)02"(3J=[Q'7&[*W@/KMS*/A_',!__]7
M_GU X^"X7.(58VO$O@(:NJ> ?CQ4),9'MBV)I6O2% 80S!5Y#\RM!',S<RP6
MP<!R87(YV(U";FVQC!MYQ?1&[1ZZ7&5A01P'L9F77N],G[6=(-4Q4R"26()R
M_H-'K:@0Y_BONVBC#Y9<IP;+,JFA+!\MSZ2/5[#PS_#O(._^=)6&\B2+A8S+
M#FK$GZW[\W5:?S&Z%??UMAOTWD_7J.7:;'+Z8FO?;%:B7ZS+IOI+KXN^1?8I
M4NHMS:3&*[+H3&%LQ;/BG(WJ\#WC_M#7R'N'X!J?KLZF24>*J8@5J1YD67W4
M8DTV?<C/H=FJ+*&LM"+/Z:<N&3E4C]LH>]_H-_K?FI_?XE\MY/+'5WB+F)1$
M6_QN\?W(]B*E%K_G$?L+8A+,Y6(O-5F911\NOL;/23I"0PF_\B(#8Z$6O^L9
MQV(74!RX.U]<.[(ON$>,Q<C[Q_O"<]UR);:78 Z3T/O</XRS;5?5'Q((4AQ[
MJ)":\OWA>NA_'1;\Q/^;\>_''BQ41>Y!)J+5/-XP%L)M03"6&^']\;C&XLGB
MJ3K%98TG&%@O2QYAXG@[3NQ%)I=#W2GDTA<H/WCX+-5\X3/ZPP-UZ $% E$C
MX?TR-5]H0?6;:G>9(6$ /T^<NBKW*GVQF2<I)M+G/ $P"2#-62'B=U",^#U(
M +^'8L+$BP6L0AMC8O+D@240#=_LR!.3MLWZG+@$D\,3N=V&''%]]"W<S[("
M4FBS+H?.L_*+A57G;=2 R:@IM_79ZJS2^X/@?J'0PLH JU:W7_ODQ^H>"J0)
M7P/$-SV.<E5"/A-,]RVY@@S*WO>GW&^TC[]!6<&ZBP<H,GP>Q%#VOB,%]S_^
M2&%,@KG"*W(\;UQ[2HQ[.\,6+<8"" &63"R,.E HKBWZP7W#N\ 8Q%B,O/_P
M[W=>CVU-S^=W4(_[AW&VXYHZ@LFR^:C7UAOB>Q@#>%;M>(Q^N2E7D$%C>6S@
MOKMDY-+Y.);1[NO.4G)$6QUX''?>F$NM^/[P^P;+KM.'O-B!I515*H$D3C#V
M3":8?T803#7RKGJ!"22&]8* /F(NQ_JSY9(OMZ0/2U?N$JZNNQZ*7@A3C2 N
M\U#-QO2?VGTTEYAI]L5XFKMH)X72/&79X@GP)/'215;*EUAIG.-_?\\K2:P2
MH=3W9CJ%,L'?\3<H^U@ P6 B0?G%(IB^3#!0X&U5$DQ[[@LF8_^=>:(O%^4^
M1<H%%MR#.\YJ'@0#!0&EA7]?M<AM\'?AUEO-O^NX,4>LGC]AA;+SFK;R[K!Z
MNFV^01_Q,\3W(6W69VMVAX!@OF*"P7/Z;E>^<&?"U8*^GLQSTWQ62E"X>-:?
M,V'@[[$0)ACT9R7?8_B]EA6,AUQ>Q<<"OOL9$TP#?HY3XQ ,^@<E'X\$8:EB
MC*$/N,]]64ZAW#$6<?_H%]XO_@[W&%RGL0""P7O&\U-#,"Y>2 S94R#(!7T&
MT>![N(Z+QV@!OX_U%^S4>5..N!^0_/$;;OG;MP/?&;2[0%R_);\G> O@]L3O
M,]G"A47Y.3]#$.;I_.CM5#8D3##$UH=W_1ODF?\'R7I97$.01]3@?@9;-IMK
M4?#,!"*?,<'QF7,W4/4G&M$=*LK(Q!*XRQ";^<L_.E#35F-5;\Q$RC*"_85%
M%>_8X3%L_F-2=.95FQ8?/Y!,@L'$'[8OMHM.#4 J:*LY*XBCN<H3>P^O/+&:
MAB*)I4"5L.&B72ARK':_VIPKE#]6L(M/1T^U5T*88+#"'7U ^;[1)E;"N-[/
M9V*W'TDP1Z+<MUHD@V#*(H_?>V<F>KRK']BZT0JM!)-Q67IO(+3>V_(H+PK)
M7BWQ\2(LC[;&B4?B^YA#N'<0C1) 4'N92*L2$B<8KY6\&>^5$HQW^3-,+@J6
M"S+%,IAX=GY"P<RU_$5C5_MSYF^B&G]L3'^X_]:CE;4*7&8X>^;QYSZE]QM^
M3ZC*',^:@<7S>?O)M&//KW)O*@80W!S-DQF3LA-/CNN\TM*"2(+9RO^.!E@B
M>@AFN,$$<S!*X!FN$BAB*'<$9-4"]])?=O_!A0)+ R2#ZW7GGQ:W^IA.),&,
MW%] /H5D""AP]!/MSSP>FP@C">98C)6W&J2"8!#'ZB03S*C]A:35&:"%8&#U
M#MF3+SX+]]O1W-@)"?$24P#)DLT5?0#1(!YEP@B""7C)N[ENZ?G[_@VOWQY[
MP5Z8C+<H<+0/A:SGY2\:C[4;]]-S+[>BWU5[7^QY42(0M7+?H]B8V8A>^7=7
M^KR=G  0PYK!63&C?EQ#H0KD7#6*8+"JGL$*[_@-%QWCR5I6,/&@G+2ZR/IL
MSU-L#PKA&%^K6(4"5V/!+#\K60;X'!256AS*=@L%#J6"#"M@D:SHT!Y6R6H1
M23"CV()1&D:;N;VP+_^GT['[&2886%;XK-*[.9+CBIG]%T9E(YAL7E"T79<C
M/@MW'-QEB<+/'9YXI%B\/UC#;7D,XUG!\KG,5I#6^ZDL2)Q@^,'YMG]"[KF_
M(>^RI\1FR5(+!O^&NVQG8PI>6:PI#5DO3IZZ1'4^[B^*8B8:EPE;,S7_TH+J
M?C*$VG>=$=6:P9Z8SCUGT^5K%6=GOU$$ T$@.1R8+2N(?T 1:R$83%*0@E)[
M"#@C:!W-(HE$9 QF_JD2.LQ*=7^62Z31[KKNH,E'BX5O'&ZM%FNSX@9RPX"^
M0!HJ%"*"U$C9!J",$=0M55YQ[C>,,,$@XVW8W@*R,GGBNQ#$SG"O6!E#@>->
M3L2Q2D P(*-P<H/2<VS"SQCNRWBH; 2#=XR8&SZ+]V\4KEI\;,'>$/</UQON
M)3SNOV4K'N[4>#'#RH;$"8;AV]V"W'/^B[QK_Z\<>X$[[&TFF%H4.#$HJ5:+
M$FPV)PT;_1,]\>?F(HT9 7PE E$K^/X#3WY,K[W5@UJTGQC%FIDJJBRO7'M(
M[D7ZPTB""5L 2H*_8R6ME6 :KU1N$UE*6,4C=A(/(!B0!UPA: \3/MPV!/U&
MYE,3_C<"_FJ!E3\("4IM7!FWVE166N@GK@4K00W"!(.^(ML.Y(147DB/+3=$
M=A64-U*/QQTL$BOF6(@D&%@R99\AI-:B:_1E1J[\C>BH; 2#=X=G@GY.BW$_
M>H#DCNELS7;8*+U+9#"B7Q \&Z3^J[&\*PN,(9B][<FSX*Y24D%%9/^^MA3,
MV4(4U!8X-A+'3UZDENU&TD,U/Q%NL[MK:-_Y'Y9P.O/3?VU)]1H/94L&ULRM
MZ<P@F,$C5Y##63'\KT81#!0VTD[7\0IMS04;K98E_.].FW)XLFESD>'S4*P;
M+MEIXV6[^!F6]?@=BYJDA$B"@9(."Y0O2 4D\,WVO*CNLVB8?KQ8* WLQ1F\
M)U]D"2%=&3_AWP=Y0:&,BK/')(PPP82SV>!JP9ZEL. =X5DC*<.J8A]%J8N,
M^S&%"0_NNLAG"%E[P4Z[8VR<#$,0#%L\N-_)1Z/'J)#95A$(!I;&ISP><"W$
M^>*1M1Z : YD.\68@)4(HL=[Q35GGRPVTY2UP'^H%WE_?DPBEAV-*'AA)I'7
MV)6!7B F@M(RK3J,HL>?:R:.78;K+!QC42*36 )KYL&G/J97W^PN;\Z\F6F&
M8'^K3E/H])E,^>KI#2.#_(@/1$,_G5ED1@7YZS-9P:V$O1F[V.J!_'BH4) ,
M^OX]6PM:E R2 MJMSQ9D$"98D%A8\'_\'@H%*:L79/=9+-QBP:S+%HD1 [A?
M_7>R%;.G@"8?*18*2VTW(X/\B6:1Y?+](KT6[S#6YMM#V2[Q//'N<'TM2"7!
ME+ %@;1D?+[UNAQ!H,F$CV\&>V2^X&O!==:)K1N'5YWKM*+#&((Y/E!430Z<
M^)Y"UG/R;],/!P^?H4'#%S Y=!;D<L<#=>CWU3^@NVK4TY04@'1F$ TV9W[P
MT4!!,)+;C*V8MA-IWD^[Y"NF-XPDF$V\(HZ&=$E31OF4,##!H<3A:@/1S#NE
M?L6-I  H"JQ*T2YB'-@G$9;P__%L8(G%R_@"(H/\B,$@ PWQ%P>+GA5V),$<
M3I!@T ?L]:G/[6'S(/9U* 'N)CS/IFPUJ;&,(I%*@H'U,(<7&[@6"'W\H>@N
M1V3SP2H]H"*]&*65UK%5& UP>\*ZPZ*CJKC)#"&8X+75%,Q<7Z[N,"TH+K'1
MENU'Z>M^T^G=.E_3,R^V%$<Q_]?=[S'A2,D!L'! .B B26XG&NR9P<^7__5E
MZ;Z95IVF4J_^"\AJ2WY"0Z(PDF"2L0]F,*_<1:#;+P6[RPK:BE<G*I)@RB8%
M8 ,?RM((I<ADL2\S_CNS>Z6-E5!FV(2'37,Y-K]0NF'!/<#/WS5#2EN%4D;F
M4BQ$$DRT+#(MB"086&P(+BL]0XB'E6B\RX& \1SQKI'<$.F>1!M0KK!R0+R(
MZV@MNY-*@@&PX1;C$02#9X2X6>0]X?EC/B#>A3Y]OB8K9CSM,(\M+"JP6)G)
M1 L76>0](&VY ]\?^HAQ@6=6%6 (P51D>+T^.GK\ BU8O(4&#)Y#35L.H7^\
MT9EJU/R$[F;+!@+"P29.E*2!@(Q@]:":,P2?>>R99O36A_VH98=)HM3,W@/I
M:\F%D<X$@XF*SR.^@9@&?I85[$'!CN]8B$4P /H-5Q<4([*TXNW S[AB9X64
M)4AI[LG85@_2@Z%0ZB_-I%7G8B<01!),M'TP6@""$7$F)LZOM]X0KBVE9XCL
M)I"')TZJ+MR"J'B >\'[AI)$73*X'?%^$.,*NPCQS+4BU00#8.\6XG&P,B$H
M$3.1[PEUS<8=*A35+?">T6Z\K$58+N%QA.]@48%22VAK,K>)_^-]U.6V4+PT
MT05$14&5)YBR<+N]E'NCB,Z>ORYB-[/F;:#OA\ZC=E^.I3H?]:-_OMV57OQG
M>WKVI5;T^'/-Z8$G/Z(['ZI+_^O.=^A_WO$.$U-3_DQO&C-A7=H/(A ,W%#(
M)D+FTC6+-H+9=-DA)A2RNE Q.1IZLH+#-9 :&X]@H.!%FB]/1$S4#Y9<BRK_
MF7^%]L>8] #<62B B-IF2$\N"Q0HA(L$KHO:BZ^)> Q*?"@!;C7LS4%["!)?
MC>.[QRH9]X)VH9SA^X\&%+N$1?3.PFLT9&]^P@2#:KZX)V3(0>DJ/3_(FPNN
MBF*D<(/%PY$<MU"4>#=H4TI$N":N@_\C]H3@/L:55F3RV$/L"<\69*BU"51<
MKLW?Q3C;JJ'8Y68>PRA1@^R\F_<D_<1](7,.XQ>;:&,!EC0J7F/#+5R)F!-H
M!P4XP\\(1(7%@RU.V9O*!)-@-,+G]U-.;A&=.GV9MN\Z3C^OV$&39ZRAP2,6
M4/?>D^FS-L,%$77N/IFRLK67O$@EH BP\NN^Y08-YU4C*LMJ 59TWVS/IUZL
MH%!+*AJPTL4U!K/BB%=,LL 9$ JF-ROROCOR8\I7//'C55/&:A:?Z[<S/VH-
M*-2= M%"T4*9[(]R+["68(VAO?F_J%.D*&S8@S\/8HJU=P4^>62(==U\@^:R
M1>%/D&!0Z1KW\XW"<XL4W"^*<ZHM\HE%"$@$]X/-A B2PYJ!XMR3Z=1=GP.E
M5I#4@7&"9Z:58%#-&^\%W]>:U(#C&F!I()L05C,6!5@0(&:RXJQ-D[L/][&,
M%S6#V*K#<T%[".I_MRM/I,''6V!5-I@$8S1X)6.U.>AZ9AXY'+%7U^D #/@2
M3Y!LO#K':EX+4$(#I<>Q$3!6.0U8!.%KQ+L"%(N5/R>U&U^0H1,+'K_41Z3V
MQOHLXA E?!^P,J*E 2.. 2) >VK*AP#A9X3[CZ5<T#4\G_#GU+4>'>@KWDOX
M.467@+#,M%K;^!Y<JB <*-5 @GH3CS/R_K5"NE_I^VK?35F@T"7NZ0I;GHB9
M)1(GP;C#@@WMH;!G58FYE(5),"9,F#!A(BDP"<:$"1,F3"0!1/\?[;^DP61<
..T0,     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45770554043728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  07,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VYNE Therapeutics Inc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001566044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3757789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">685 Route 202/206 N., Suite 301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">775-7936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VYNE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( &5 9UDD'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !E0&=999!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ 94!G6>\W[ +M    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 94!G69E<G",0
M!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " !E0&=9R'1-VUT$  "G$   &               @($,"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 94!G69^@&_"Q
M @  X@P   T              ( !GPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " !E0&=9EXJ[',     3 @  "P              @ %[#P  7W)E;',O
M+G)E;'-02P$"% ,4    " !E0&=9'#AEZC\!   \ @  #P
M@ %D$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 94!G620>FZ*M
M^ $  !H              ( !T!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ 94!G6660>9(9 0  SP,  !,              ( !
MM1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mnlo-20241107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="mnlo-20241107.htm">mnlo-20241107.htm</File>
    <File>mnlo-20241107.xsd</File>
    <File>mnlo-20241107_lab.xml</File>
    <File>mnlo-20241107_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mnlo-20241107.htm": {
   "nsprefix": "mnlo",
   "nsuri": "http://www.menlotherapeutics.com/20241107",
   "dts": {
    "inline": {
     "local": [
      "mnlo-20241107.htm"
     ]
    },
    "schema": {
     "local": [
      "mnlo-20241107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mnlo-20241107_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mnlo-20241107_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlo-20241107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlo-20241107.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-24-045998-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-045998-xbrl.zip
M4$L#!!0    ( &5 9UF"K]F5T X  "QE   1    ;6YL;RTR,#(T,3$P-RYH
M=&WM'6MWVCCV>W^%ENY.TW-B8QOS3,*>#*4=MFV2 ^EV=K_,D6T1-#4VE>0
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M@/G?=-T5'8&^!H6##J<73XC'PGA,N$Z*D_>@WW]Y;5>L@YKQ,?W0YR&R#I?
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M]2IM&PS'M+W&\>$]WGSOW74?V#P@L]X?4$L#!!0    ( &5 9UE(.UFQ(PH
M 'U5   5    ;6YL;RTR,#(T,3$P-U]L86(N>&ULS9QO;]NZ%<;?]U-HV9L-
MN*PID9+(HNU%E]L.Q7+;H$EQ+S8,!O\F0FTID)4F^?8C93NU8\DFJ5C=F]9Q
MZ/.<YT0_DX>4_?K7^_DL^J[J15&5;T[BE_ D4J6H9%%>O3GY>OD!D)-?W[YX
M\?HO /SYCR]GT6^5N)VKLHE.:\4:):.[HKF.FFL5_5'5WXKO+#J?L497]1R
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MM[?+[8'Q_L">U\KVC\I$L:?='Q>+6U5?VH."^K/6IO>1!.8)I0KD$&. )4T
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M[QYLQ/PY6P>[IGKW#3J&AN)WR>X_2C,+%GKUR<_5VS:,62I3FH-,I/8>/TX
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MQF]O7ZR?*9;?UOGVQ?\ 4$L#!!0    ( &5 9UFBRO_NPP8  $TQ   5
M;6YL;RTR,#(T,3$P-U]P<F4N>&ULU5I;3^3&$G[G5\R9O)YF^F9W-UJ(.&3W
M"(5DT2Y1HO,RZDOUC!6//>HQ"_S[E V30& 3"_L(YV4N=ME5]=7GZJIJO_OV
M=E/.OD#:%75U/&>'=#Z#RM>AJ%;'\Y^N/A ]__;DX.#=OPCYY3^?+F;?U?YZ
M U4S.TM@&PBSFZ)9SYHUS'ZNTZ_%%SN[+&T3Z[0AY*2[[*S>WJ5BM6YFG'*Y
M%]N?34=<T:!,EA/PCA&IG2,ZCY:P/!A#8\BB#/]>'5G.-1=<$&Z$(%+XG#B*
M%V31J*!MD(9!=].RJ'X]:C^<W<$,W:MVW=_C^;IIMD>+Q<W-S>&M2^5AG58+
M3JE8[*7G#^*WS^1O1"?-C#&+[NSOHKOB)4&\+5O\\L/%9[^&C25%M6MLY5L%
MN^)HUQV\J+UM.M3_UJ[95R7:?V0O1MI#A'$BV.'M+LQ/#F:S>SA27<(GB+/V
M^Z=/YT]48C3+&@.8[!:NF\+O#GV]6;22BWVP;17>5TW1W)U7;60[L_?GT*5.
M17.WA>/YKMAL2]@?6R>(Q_,-WI^TL6>,JM:P;WK==_&'^=L$NU:\/7^!!QYN
MW]KX_W,%;ANH MS#N+>DK/T3H;(-8IWV5Y;60=D=708HEF<U/EFG;M<DZYME
M8-3FT@,Q/D0B,VJ)4U*3+,^8YIX:G8FGR+6N[="W+N8[\(>K^LL";XRQYZ+]
MT<(J.DB?J;O'[W5V[P&Y0MEE'J..68;&BJB(-$83#2X0S9UP+H**>3[([,?:
MGEK]..ZGR<_J%"!AEMJKL\D_X\#3Y^-!8K&U"6]$_+HHP_[JF.K-&+%JZA&0
MNP\+FCN?H=<14H)P<1^5KSK7>=9@[H9.<HR(7T(J:GQ"PG>8W)?@F?:&:<*%
MYD1&)HCV7I' <BNMH(9F=I30/U';BP-\^AQX/99O3(;[!/D)5D6+1-7\:#>P
M9 XLIYX2+FV.]AM#K#3H1":B9[FQD>I!7'A):R\JB.E283"2DV#"&6*5;'F.
MJ^'M]W"W#-%*R*,GX)#/DBI/#'.<(!29BXIR9H<M9"^J[<4%.74N#,'RC<EP
MBDDMM(GM0VE72\>$D'D$8H5R1.92$ .4DX!5/,UDA$B'K0U/U/4*?C;=X+\>
MNTED@'-L"=.V3AWBGQ%X.*NOD<AW9W6 )6?,YXH%@A5-AJ#PG!BK%!$^ QMH
M#C0?1H4>1O0B2#Y=@HR-\R1H\Z$HX<?KC8.TQ.X<:UX5B=#8H\I,..*P]"&.
M>0A,T=Q0-P)'_M#8BQ!JZH1X)8*3B/Z5O3T/B%41B_M)QX,C6M-<Y"Z28#$%
M2LT4<;R=_S -Z(/P-O@1J/ 5];UXH:?.BS&PG01)3D/ $.P>OBZ*"MC293;Z
M@(LBSP7VS9Q+[)MI1G*?1Z4DDUS+$0CR@NI>Y#!3)\=03*=$C#/\^3%=U3?5
M4GJ7X<(7"1-HO918*EMG@(0L!.6DX"(;(V\\4]QO)D7_(:QX):!3XD17&'U,
MEZG^4E0>EM%:[36+1&F)W-8:ZZ(L4X0Y&X5B+% ^1FWQLO9^[)CPR'(T:*=$
MD<MZU]CR?\6V*YREB-A9*494FP&E=8%8SQ5F0*^<,BH+?,3,\41W/WI,>)HY
M$JQO3(XVZYTFL)W=A@6I+3/(8A\0"ID1&QUZD"O@5D4AZ<"-F$?:^A%@PC/,
M5T/WQB%O]U?+RW5=[1LH#Y&Z0"FZW6[',*,PEP&0'!?!/%CIJ,T&A?W/&ON%
M?L(CRT$0OG'X?TY%TT!U5F\VU]5#D[1;VAR;(ZDR0J&=O'G7SN"P4]*&!B^H
MY=K"( Z\J+8?$28\OAP.YANSX7-=%KYHBFKU Q8XJ;#E,@N9,\PSHI4U1+9;
MM%I12:*7S&?"9QR&58W/=?;CP82GE -A?&,27"9H&0Q8V'9[].WK'>EC1#N6
M,G@L7;PDE&ELA2SSQ#@%+:DU,YX'PX:]Y/!UW?U(,>%)Y4BP3HL<Y[O=-:3'
MOH 2#A@U1(!IMVU]NX%/-3%:F9R#IBR:,2GRS()^1)GPZ')4B-]Z00%_C8OB
M'>/NJFA*[)29XGDF ]%6::R'HR=.*$&HTLX[(QR#.&PY^9/&?G28\+!R$(1O
M'/ZK9-M79#_?;5Q=+G.A,Y!@2 !MB93 B0')27!> U+7Y6985?E$7;_WHR8\
MCWP]>!-YZ-_?^K6M5M"]SI/K2#WG@5B;8=(*X(C.HB!&NJ"I4$XX/LJ#_UAK
M/PY,>.HX&,I)3!O?;R"MD,K_3?5-L\;%;6NKNR4XCIE*,2QS+-8ZV",1YQDC
M2E 5E,\4#&PR_T)Y/V),?MXX'-C1^/%N\0S*"SQP<O!PHOUHW[X_.?@-4$L#
M!!0    ( &5 9UG;22?]UQ\  !BJ 0 =    =GEN92TR,#(T,3$P-W$S,C R
M-&5X>#DY,2YH=&WM7>MSVSB2_WY_!2[S2JHH#1]ZVIE4);9G-GL9)QM[=FKO
MRQ5$0A+'%,DE2#O:O_ZZ&Z0>UL.B+$NDQ*D:1Q))$.CGKQL-X.TP'GGOW@X%
M=][]U]O_KM7896 G(^''S(X$CX7#$NGZ _:G(^0=J]72NRZ"<!RY@V',3-UL
ML#^#Z,Z]Y^IZ[,:>>)>U\_9G]?WMS_22M[W &;][Z[CWS'5^>>5VVFWN])I6
MN]VU&WW;Z#IV7XAVVVKT>KIC=?[/> 6/PNWJ&1F//?'+JY'KUX8"WW_6:(;Q
M^8/KQ,,S0]=_>$7WO7O;#_P87A;!P^JC:F.AI5A\BVO<<P?^&8WGE7HTNVP'
M7A"=?:?3?^=XI=;G(]<;G_UTZXZ$9-?B@7T-1MS_29/<ES4I(K>O;I3N?P3T
M";I'7Q]4?]O0CN?Z(NN_86*GK[X-W9X;LVZW;LSW>-UHZ(\[&C#NQ4#+$1^(
M^E_AX!63D3W_78TF?66K&WX['_%H %3L!7$<C,Z0B/<BBEV;>RDYB#+J<DI?
ML]T(ORUEAVHK#L(SHP,MS1#5!A$0T<ZIVMB(JO_\U_45NQV*B(<B@;%)]E6$
M011+^-&-'/:/A$?0.R7#O[H^]VV7>W"33#RXB?L.^Q(%]R[(/ON >B"D9'^$
M#NC% B.6T<*$7H;<<4"!:I[HQV=6*Z..ZSM F;,:TFOGU#$RZE"+9VX,O+#G
MZ-582J\?O^N89NL\&UL1.C5//Z-1-YI(,."LJ1OLRY!+P<P>NW=C%^0M8'&$
M'!3?;"$<R80?!9Y'YBP&OHCXQ^^:W7-V]2T4-MJV.& ]P?J)YXW3>^%'UV>7
MPA:C7B89#VX\A%O#&G:.1:ET!#Z\C-MWK!]$;.0Z-;BW68G%0<5"J3?P, PD
M2,0]\-:-))*U-DR@$ZG &)S=O+]DH,><N$?29&J*T;]G5T0F)2 0_V@H45C)
MWU4F;[G57O+47XF,W?[XQ?W/ C4-$UC\X>O'R]^N_GQ_>_558]?UO]?A;W!/
M.O#C=T9+/V]KB@#@^Q>MZD??KK/7UUPZ_-^@89USNN<->TV2HY_C-_IHG#,@
M=SP4++UR$8Q"[H_3BV\TQID-O2,W)&/P7ZSG!N&01R-NT\M N6WU#'#.3B2P
M!Q31$??""T($*H[;[XL(6. 2>HFIGRY0*D;C )"&V<,H@#< 6_L>'XUX'$1C
MLO7N:)0 84;"4<_:@>^ % 6^5)(Q!(*QQ!^)F/E@7C1HTN'XJ!\DO@T/]"<N
M)#,2'.Q$GQKOIP./AY$0](N/UF0$K!FBH7+@^1L1QC,TM_24Z'AWJ!R1 Q3J
M9:XH(5=47Y3*LLB>WL[,BW[^IT""QZZ?".35B-\)LN-@DZ%/,/Q!A&,&9>3.
M/9(9F!TD0-2'  1PZ'ZXNH66&AWS?")"ZBD^DBSU%TC(3-GQ<T]X+H@.$]P>
MXLU.8H-\P!47"<O 6!#/PB F@?)2A\$?29D&;^12@C'B:)12H1L3SQ\+E>-*
M 39(:IE"2.XZ[)+?X]]@]!_NR3M7 ]PAI(N^@/IY,71%']R6L!.R:I_[?=<&
M]P2RA;I59U,:1@+M#_BS:,$63FU>%(R(=K/F\,?O&NUS-'[*A4+30<0]C7VX
M-(&S'IA"; .H#"P@L!I$VAPQ'U"L047=$&FG7D\:.7DETA+?0%= ;>$=I!+T
M0H\C%(N'KF3_5KBLSF \/ +V^#;T%JP!<&Q,C\@8='@PZ]]!+G!$\&N +YT@
M ]7XQ,H;[&'H K.ALQGS$]"]2-I!)!2W):B$"_2%P<QH.[Y =19L"+T1>I_!
M#NJI\A<H(FBA/!&+V?[YH&Y*VXE8BCR(*@A4$(T01*C[QH)']51 \BMPX?1^
M 9V3S_E*DLJ^N*$@&BA@+;>S9O/A3&L^"'GQ<:[$+LM'KB01G9T7@)GRQC7N
M0$CK2A!ZD#0Y@M] 5D#G$@^L#_=K'R[G-8^\[$IBK "7<\38 ][<#'J\*+K<
M1!(7L"1!R4<&1%E:M!]@!WR !&* :@U7)J%'%G0 (\E7+ 0?I/AB)O98;R?J
M^R')<JX@P'ML1,$RBUR14XJH>0BN]9L+2$O W0T='V[J3":]OZ QR4*X'1!>
MG=ZI7O7 ,SJF /SOX$2G8(@@J.H+ ;NI-9V/T29>QVS <,4=<X*DYXE:#^YR
MEKLA>%<6S-6WLD25\N7IPG+E6R)\KZ\O;O56HVLUVYTW*(J<12 *P0A>!0!L
MEK$:NQ?@Y.$K LI4-M/$P#WW$AZG((T)Q%'<'FN POHB5F% &FX$=]!5"F\0
M"@&^KSD<1I^9@8'P%"1 ..\$$M'KD')+KXT? +?_0&U9/R"H13\7<8HDWJCP
M)5(JE/:3X DF&D!$99W=9(J!V*<GL+/3H3(!Z BU[K5!3F#N+Z.WO&'<C@*I
MT Q7N,V)DL&DA_"V],UU]BN0)WC(")+IR13E@'*Z 9!THJT/PP" \3WV3/BS
M'<L TB)%'ESP9_0,WA"$I'5D_S*\/WF=RK6 @$2HQ&&*.M/69@E)-.,8#*@8
M#9AK=E3G0;>$+^&W&5(^U>N,$X,H2$+F)%%&D<R:KZ*,&AS8PHPOD:C--0_C
M#, D949&A7]SPU)$6C:>5")V@XB*!7\H:* 0XS'>F0\X*LBS-\B3VZN.X*L+
M"(9Q"9I)H2^)=);W^1VC2I79>>QL)Y'GQ.OBKWT(X4#_T_@/[T67?U@@=#D7
MON)DV.H!WZP>,(U3FTD6P9 G^9X4+<EA\$ Y*QZGD34!H8'P142VY4%XF(/P
MX"OB(C*6?J",>R0\^I$[]Q#.@CVZ!S$';_)>2B%E%K'>B?%C!S?G])RQ#U2T
M(>B(.(2^T!)S!,!1&:M7TG =$0K2HLRMS!GF#"J;&5=[7@!V$M^2#O#QRUSP
MB'8\\R"0#3NJ8'--^ .(_4=9,F0N;]=S@<71'?83W@96WIN\3TH^EAK\;'L)
ML0KLS<2:C-'W8[@.KU+&9F6[0%B #3Y%]J$,@(_259-#T5 D>+\+;P.YC<!P
MRR79N&<&[)5I>SZ@_))JJTQL&[0!XI8L^%IIDS05980>= 59GX4CV6TI,$TS
MDF )9R 2ZN4H<$A-:W$ (P&=%-C6OP'MS O1XGV@Z"E 6"9@VHKYJ&GN;0)J
MI, 4-N >KY_:TN8:\7PT1;61;,Y.PJL\8^"?D26"[B],RV=/I9A$GS[">S+P
MDGCU(R\_I?RD<-%<F+&LGD#]'493C1U * ) \:[&^]#7,^X]@"UZ]4(U#,L9
MM^]TWI+Y\X7)#YIV/Z@W/QSF>O4N*S>X6C?9L_$,<D'SFTT8Z 670Y;I=GU/
M-%]D.';E/<G@"EJG)G[('69#ES7ZBX&<>\]QU@EL+5A7,/.4\J*+9+$1&,2\
MYY&%3= J"WK-]VV];C(8A4?CIL;3609P$Z 1SW\+7S>>22PJ$TQLN$*!EGZ"
MJ GC_E!D( V<29 ,ABH+ I=SNX<BR]_-$#,G-@#M^&"Q _:#;2I]1D-K-PVM
M85D D3E.1+E2)D*!YB")9<P)OVB/?V!A)&K(7XP&>!0!"""P$B:1K?)G;:W3
M,+5V0\]:A@X!]!DA[HT#^XYQ1-40]HG(=N&!$.20LA7?ZW6@CD'967KT.&3C
M*\9%B9"'-4M9+X!7T'%@'E#;R"P'N4O 2$H[TV!XDQH!^&!I,WDS;ZQA< 9(
MDS*>P-0H&',OQB05O7\:UZ:%&#_)R2U\$ DQS<E]NOJ,R!?B-JQ[P$AKE )D
M:,L-$@FH%3@@?*FJ+AB54Y(P(C*P!7\1>K<0WS])\"78%&6U9M67%#[V0&^P
M 0QFC';C8+$,69!^P$=UMO.8LI@*2@@;T*/@8+U(HM/"'A)#S$R!=,D#\8,Z
MIYPZ!KE&^QQ3 T_T=8)\LY36>B5^P"CQ>V,&1: ZA_@:/YZD,+ R6RH;W:IW
MIW?B)(+>J7=_T.8F&;ZWZM:<:=FT/]9R&]GC]AVFR7VGEI*]3_^=[XL)MY26
M3ZF "3+P6>"!<'+&B4"W?:P2R6YPIKS@4@:V.\V<(2M_DJM*1N9F?.=#^^7S
MOSQ#67/MK2JNR3)=P,1F79_P!QOYWJBW9_D_->=@"3Z07U"9!Q*7Y=.D=?9Q
M.I>@,3$*O6 L1"W+$DZ(,J43$ V\T*RHS,X,0>26^I"9&8J5\@^@00:^+[SR
M@P:,W'Y3&5@:9E:J$9$?F1#R<'@BG5*96*47[D=.TAV4+(.G^?8LL*4T<+Z^
M <RMOL9Z8X)9D!$ @.X/!-5ZU0+ (#6J^CH&=;D6,?,">6"=R'JABFVS+Y-P
M9CO7;$Y=L[+5X*N[BYA[ZGWY]-4K^J'\>&N^6;..!6+SS68=5LU39B"=@P;+
M3_YZ5S!Q__DQRM7T(+)=45Y>9@"\MOJ9ADOE+*4I?*]GR"GQ79S/2,O3 86)
MF$.3<Y6*.%]!%;?8^P@S#(B1'A5LAP!*0+I'&I6\. )+<)7ZH&&$)P7$EB.P
M/Y,91C"58&N5?:<YG/F7(ICQ<#*%#\CP>J#@OC+\@%QCE0:9]0BIW@D?C#+.
MSF8%"&X\WJ[\HC "]BLN3PH(*"*)T[&N436,(Y!'"_7PP,I[%^+HIZQZO_^"
MPWEX>*C?C\&,SG2[#A)R($]#?4I3O2,^9DDJX ^B!Y02DRK/L=(DO.2XT@87
MD*#I[X& I$)-9>CLJQ@DGN+1KY=4$1D)8)O >>Q[(4FVY3!(/)PX]%'6YR/2
M[+WN%/U3"GB"Y15G<24%SFO32@36AP#&'\A)\17[HWY3!T\XS3J#:EQ]2P'+
M13 :N5(2O D3&(&-!H-LCPW.B7N>S!8$]&PNXYSU2X?Q/1]3Z@(#%/GE\GJC
MPZ2!_AX,01XBCI4C\O!]HBC\D]L7-[;+WCM@%,C.?_IT49"^=8UVS6HV:Z;5
M75R2N7>[A>L5R1TXP@Z4LSDC;5=9QK_Z*6-__*[5@"?[0MHN3ZDZ:]H*H3[+
M!?06WA:Q_Q4 ,!Q^^#ZM6/V]%$@>2$+U3JW1[-2ZAMXJO(02=^LI=TE*D;;Q
MM\()YW+;_COBVD>&?=4JHWT'J;^[=X)]$&,1%:1#-WS$/D3!@U\0;:%.6899
MZ[:,FMG4S<)KRPA8VD..DJ9(/NHA.5%7\BUM*\NUDZT%>R2*!ZT%>QYC][W=
MS05/: 8A&K,;".K5-#.$/CRBH@8(61_@8^U3@#7*@^D]B]AWXW#[D+-69,-N
M<65S&G.E1<DJ^TQ#]=*ARLE0*1I+"SE'@OOI[ L5JD;N/5:BSD1HG^ ?%4D"
M'3'.9^]51;71[39GBJ UUH/ WP]BE5"A)(LV^]9HPH4TR<-[$!W&8XPBI]6S
M$,].%B]B1/FHG'\ROP6Q91)CI#M9DI].7<W<025(V;K"F960&$+&T$GH"F8^
MIPO*5RQ(F&]X?K$_CN60N>@T/B_:="KUC3(]?XEI]5F4^&"BTEHCS+,LEP]:
ML*&XJ]BGX)66EDRG64&IEI-,=BIX[WFSS9& NX]2$FG&$'.!**EP'2)SDIX^
MS];%K58<> <E25<J%BVKXVD&=2Y[ NJ$&51VYP</GG &8C*IF\[BJ'*^OIQ9
MRINF;Z9T 4<F74S.9\2Y5V_%.:A(9%/)M,#&E7= +PS^HIB[_B37PJ5,1F%6
MJ8>I6\KXV!S32T""9&:+$6A'I7Y9-K/DC=,)+UH( M_2*A]<NB%%C*2)AY3E
M PUVU<POJ/9P+4TAD))"]9A:G^]T:L^4=<GX-K4PTTUA)J1>95;2C/:*#*3:
MOXG6TRC+D%:S8>HI6^*2DATX-C$Z,@;CE]+VD252+:[JVL3(J3T;;$%["O'[
M0$V_S!F@)29NW2!6O3+H(55G9]FQOH],MW!)&[/:32PAA6> D8[HQ=GN,ZB9
M$2@@+B&@9'D$H_ \W@NR/#>6":KU-&E7LB75*RF09B_O>8257BCK:9)2XN2G
M!Z-&:N B"1APMCT-KBV-:*\4:2>4+Z25M#2$%7(T:W- .$%.<=T-*CTEF'#R
M YK(YA.F*C'?^57Z,:,&N/(4WCE=*K%:],$["I$MIU#Y5-S0T,GV7/D*0V&_
MJBYF>[JXC^S*>]]/J#">%M1A;A<]M*'7_F<RJ8>3O^D4Y&0-O65H:4W? H<4
MC;+$K1H9. 6:[,%_\Z9RT3 #:5"LYLN68]+[)ZPI5I" J((0D#L'<Q("X(6!
MHBF2&6RA/77H,RU]40OA)JZ>7DMA5,SOX,5^,),>QW&IW8[2E+/WI,E2*QC[
MM+0+;*X$;:'*+&6-42O<R$Y&6$EKH^3A]@UA3-U%VC[@5%6$*A8I"^GQASK[
MC<J+XG6V4&/C(,ER]&@&:4%/$JKBJY54)!?CN/9DAFO.>Q0KA;X2X,+80AZ!
MX4B-7FIQTWE+G^/;<+PP1B JSFW@=@M\C#7K:I$D=P06OF<R,[\,',)H\&C;
MS<>=7'1JK8Y.G8UW7VV\.EA$>SAZKMM,]&]77]]_N?KC]N/%#?MX?;%17<)!
MQ>#B\_7EU?7-U26#3S>?/WV\?'\+7SZ\__3^^N**W?SMZNKVIO"C>$UNS$$<
M$Z5! P 1,"Y3PZV*:2CJF)36X+9:;THP.)\#/@6HG*^OZ>*@S%)%X#IK!/5"
M*<ZR#^< OR @&Y^Y/KV9'MIF]]]NM]YI6JB^,>AL[&0O3C6[3IK]<^PL7FOK
M]:[57'E9KQLKKZUKUC#K3:.U5;/KKS4M\V4ZV]ZHV9^)OHK&P$4)OO.75]:K
MJ?FE]<UG.C-HK6?6WII;S? ;WKRX+_/"T@=B^/X-++F%Z6X(EJY-%.'IT1T=
M(6;Q_QP==B<9J;6@8E*TG8'G.@Q'=EXN4LVMF-V)J!P19:P\PK.8AK1M(?K]
M=</&+18*-6C<ZV1FDF -EU>-=B7[9R5@$S%ZBIS/:2-_)W,S/\U!EXGY%VGR
M5@G!?/E6'B(_&OI6C'KI-G:DS(S^U0O#V,7R2CW;3H 2"8\6SC]F;Y[1ZZQ8
M,KU\Z-\_:XBS0Z/EN(4:F]'2S+:IEED\9YB9'.<8[BX-=R5T91(Z""U:IGXX
MH=N1(RZ'X?XZOZW)2F]LYAO_4BTJGJ@UVCG%; VK7\JV;8I3CI-#S<;A./2$
M(<BR=GZ )87KF+JO.T\*<JKE(-G!$DNW8MK*FFV*"0JH*Y;6-:S2H[4CYU++
MU%K6 ;ET;%:MZG#5X:.&Z%\B$>(!5-.ZJZP&DJ_/I1XG(K0T2\]K/BO8OF<F
M@8]KMBKD7EG@,D]5W>+&CVQ^SN(Y(<5F\Y8ET?"VI36MYG8P=N,)W+*$(4?%
MV6Y3Z[:V#%!>EK,O,$6:'<[PN+8J" ]D=*X#OV;O=IKT::8<>@(U9P\K;UG
M,.6SVKG<'S"U0(STN1;T:[0@ZMG.LX2&U##+/W5ZY"PR];PS0,6;:"RT59AU
M9V&:R)CN]CO):)QD)L/4F@VCRF04FTF&UC3RACE5)F.G4*=P&%TE!A:1>I4<
MF*;_BAE!5KF!YUK#]K:@MA2I@:+-"*VS/\MMSO-#[6.L@LPW^&+K8+NE&=W.
M=I"D&-;U"419B?"QBW"WK;4Z6Z+JO?B1K!>31< DH(==1V3!D)P@P1*WYR=O
M#]C%/:4]#A<>?'+5YCS97BXW>(C?,/" 2C+='89=T<9 U>*G4B2\UR]FFV'W
M]E,U.]3'%VMCIQC;K)O-PC!XN9>ZQ:UN6,C'6%:<&VB? !8I$>*PM&[G@ 5)
M>T+&E<P5:6R&UFIV"YLZSK<:I 3F^KUM1\G,N8DG-MO<THQ6WJQ -=^\9R8U
M-,/(:Q**-^-<&I-PE9ZIRK(S56=.<SJQR69#T]O59'/AF=1J%'>R^>@0P^.2
M-6\:R9\8>##,:MUHT5F4NPRE @[;6X:Y=7;/M0ME=DA6[A7E%6K8,Y-H3L$\
M+SUN*(A%V&0QV*?=((7CJ@W"JJ^\(495]54"SK:UIK5E:NF@55]'4!V[W=SW
MA$J'/>U\Q?1XX ]JL8A&RZSH8?SGPC'2U3*[$TP'S!9T!U5JX%GHLDH/[+ND
MKII6V'-VX'2S @</.*N\0 F2-Z>S$FPMHMUI]%C2 /)9&&)C8I0(8!P;@PVM
M8>QZ7=B>D@1'L6M,:H=V@TB.3CBW24SFI46)H,RQ\;>C=9MYSPO8%WL+O)YH
METFJP_5P?];]L(M-\!CH>#0YIOX"GH#N"]]>9^R/9!E18;2GT&V< LZ974KW
M4[J(KCI&;-.\GFG5EZ76Z+OK.V!<SFK=L%C._4LD^B+" ]XE\IZ8S;[7Z_!6
M@X4\8O?<2P3\W#UGIJ[!S_B_.EP83&42#X,(7N<P'K/)\:4*+%BZQO!T2C*H
MV8F>Z26#+EFJ73_(VG.EQ"4&M'%5$N/!]$CD[=JNYA&J>82*32\ZF5!&@X=(
M+_ WL'9&\X7,G='0VDU#:U@6W0I?]6Y'ZW0Z+V$%-08MAL*.W7OAK5X0?Z09
M^FH*I6)0M1A#+=^$;N/"+.XQW"44[#.S>>C&W#LQH-3NX.D9!SP LP)*F[$)
M7&\C[_&$!05*I3 0MIV,DG0=IUJ?$8S"2 R%+P$\,->'[^+$$(1UP/,Q*PBQ
MT5ZHQ3T'*5_RR%AN(IX*IO:1+'S:8#BB[]IN?&)0XG7;Z&I&H_.F@A&%95&K
M:VB6U3H(BTYARD"51BR;.*AJ)*94:N%Q7EN>AE[52!2?OYV.ULY]7-N>BR1.
MH5)TZZU!-RR;4(1=V(CU>>)<N%!P\UWC=DR=8BOY5CN#[Y9"!P:+E9946O+D
M2JEM-A\OAI:0H_PYQOUHLY6J,RM\TU$V,$H/ TG9]#/:^<R]%^</KA,/4Q+,
M/I6.19\^PGO0\R1>_<A,IVT(^T6T?TZ:M)O>HT6[,W^QMZ[SRRNWTVYSIP?8
MMMVU&WW;Z#IV7XAVVVKT>KIC=?ZO_2I[9C@I- OY0-1ZD>!W-=Z'\9UQ[X&/
MY3P51JY?FR7Y8VHIFKQ[VT.>+?;SH/1<P"A$SW_^Z_J*W?[MZNO[+U=_W'Z\
MN&$?KR_J\YTOH!A<?+Z^O+J^N;ID\.GF\Z>/E^]OX<O-+?SS^]7U[0W[_"O[
M_ 6&=?L1;BC\>%[_4;^I@V'Q/!Y)YOHL'@8)-.A(C8EOM@#C$8I(3<8SA\?\
M30F&Y//$<6/A+/85#"\:M*D](B-JX_!#*<ZR#^?9?@JN3^W30^<C'@U #U,C
MUER2?D0*J,M3#<5Z"M32-.9(WYQ>KM.E1QY!76OH]8:Y^K)>-U9>6]>L8=7U
MSNI'US6[_IK5:52=+5=GFQLU^T3$_&0&I+MPZQ) JRQ&H<K@;X>1$.QWN&\H
MV97O" ?=ZZ3JB%FZMD$E\-&2YQI^R4&=YTK13*"VZ38_!2<@%JMM4DJ^DU4T
MQT.SU;7,E315TO0\:3J%S06_BGOA)ULNY,JSCOK0"Y>J3AZNDZ7;+*\L=U:$
M/0QACZ["\6LPYEX\9M$*=_#LZKC"C?BHCW\RR[^\HY*X4DF<4?YJX$KBRB1Q
M#6/+FK%*XBJ)VW+!0]X"E^+5TQ=$>-85JCV9D3BU/?#SH[GJ:(,RL#4W9*K8
M6@*VYL<E%5M+P-;\SG^?QY \JL,SFKFV*=MT\<(IGD11]?#%3_,H7O:W+'=6
MA"U*^K^$T=;T"-JK]-CZ[;<S+,,FE54;+[)I9WFFN(04/+*'M/K-$??""T+<
MU?;$MNTP=,T\9")KUW#E.+ED:991,:G@3#(-S6SE/7NBXM*^#9ZEF9T#SDZ>
MVFYZOPD?@*5';I8[(]=W91S10L 3VP+'U+JM V[2=H",7PF99&FZ56UX6' F
M 6;5S2T/>:JXM"\N=;5&]X"J5"7#JBQCN>[<]Y'LAZOI6,PUOL@.:&6TFAB>
MY#[ ,!<A2A1>'A5G6]K6%6.GP]B2\M8RMD\J%&9'JXJ_JV-W4VNWB\K?TYJ=
M_!3(JA9TLF<OP 6]:^3>LK<8#J4J+ENU$[-F6HV*J<?F15Y;NM9IM7?'V(JW
MQ>$M0(2&F7_S]$.C@^*E0<IRYRX+9II+3P<LDGQ_IG-NU,DV&O/%J=7)=*OS
M;8K.(J-E52PJ-HL@6MDVC*Z8M"\FM?7R'Q15$%^Z/)F!*0S6CX(1C-"/73_!
MO$:@,AR!+UE/](,H.T:.Q?Q;M?IU)N-A:D9SAS%4%4 5A+$M\ T[S&15K"T.
M:\VVUNY:%6^/DK>&UC;UXO'VM,+SCQ.LP(0JJ3BQ^)S.K#+/J]BB8E/%IHI-
M%9NJ:'T_T7H5F9]"9/Z"G"P<EMSVM+ZG!E]P\=UQ_J%(TGO: 6J5?#A>WAYW
M\J'0;F**BQQ7IM!(.#/(B,H$6-!__D1&A="K0.IE#4G3R.$A*O;L/;3H5MPI
M+G>:C1S%RE7V(=]!BN!"ERUYJ +2HP](JWS*MI'*$4MPV82XI34[.US*4HEQ
M)<8'2B)U#+.2XTJ.2R['IF:V"FB/"[QQO05#<H*DYXG='+U:]?)8>GD*\2=E
M>4,!FCGDD5@S#ZZQ'I>NK;93=KTD%LYSMOTZ4D=2)E^AU\T<:;?B[:]7B5NI
MQ,VH=YJ5N!6))4<M;GJ]58E;H5ARU.+6JK?R;PY1E2)L!E+3U0^O/0"K;QZC
MU975"=OCU2=#AJ/6OIRC+[9BZG4][R;%^<9_X+GG2H:/7X8!RQ@YG$LEOY7\
M%FK8E0VN9+CL,HPV.$>MQG[D]_02U#O(0I^H-N8<?>&U<8O<=4&\R>[FZBOY
M+:O\FG7]66O1*ODM!B-/57ZWRJY7\EO);S&&_;I5[SRKVN\%T7Q5(U7ULCR]
MW.EQM_H2:TG?7=\1?GQ6ZX;%"D[_I"_"81QZQ0="!:F2!4DL8XA1L82J]G3(
M.B'<YFN\U;#S>Z#BV>*&J34[[>T.DMR<&.5;Q7\\',83N;<\SO7T&%Q2'J,6
M=U^"R16?"\5GT.6V46 V$Q[Y.>;0+OSKN/?OWM(?U=4>7DQ[G5U[A+<;N!5H
M&$@7JTC.(N'16?;G#ZX3#U,:S#Z5CD:?/L)[,D OO_*1F0'9@&I$M']6FMBG
MYCPIYO[V F<,_PSCD??N_P%02P$"% ,4    " !E0&=9@J_9E= .   L90
M$0              @ $     ;6YL;RTR,#(T,3$P-RYH=&U02P$"% ,4
M" !E0&=9G&AV&GX"  !U!P  $0              @ '_#@  ;6YL;RTR,#(T
M,3$P-RYX<V102P$"% ,4    " !E0&=92#M9L2,*  !]50  %0
M    @ &L$0  ;6YL;RTR,#(T,3$P-U]L86(N>&UL4$L! A0#%     @ 94!G
M6:+*_^[#!@  33$  !4              ( ! AP  &UN;&\M,C R-#$Q,#=?
M<')E+GAM;%!+ 0(4 Q0    ( &5 9UG;22?]UQ\  !BJ 0 =
M  "  ?@B  !V>6YE+3(P,C0Q,3 W<3,R,#(T97AX.3DQ+FAT;5!+!08
..!0 % $\!   *0P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>mnlo-20241107_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mnlo-20241107.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2024-11-07</startDate>
            <endDate>2024-11-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001566044</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-11-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">VYNE Therapeutics Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38356</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">45-3757789</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">685 Route 202/206 N., Suite 301</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">775-7936</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">VYNE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
